Bridging Local Startups to Global Markets with Elia Stupka of Angelini Ventures - Part 2

<p>In part two of this episode, Dr. Elia Stupka explains why Angelini Ventures established a Singapore office: high-conviction “boots on the ground” in a rapidly transforming Asia, Singapore’s role as a multilingual, legally strong APAC base, and a maturing local ecosystem with A*STAR science and clinical excellence. He describes EspressoLab, created with Enterprise Singapore as a hands-on, transparent program that helps earlier-stage startups avoid common Series A mistakes, match with global advisors via a bespoke “barista” model, and use of an AI augmented diligence. Stupka outlines Singapore biotech challenges, especially the lack of industry-experienced CMOs and limited talent pool, and suggests Singapore should combine local and global innovation as a hub. He discusses China’s surge in licensing deals and the likely rise of global Chinese pharmas, argues healthcare will follow “faster, better, cheaper” global dynamics with regulators racing toward higher standards, and shares founder traits he values, plus Angelini Ventures’ focus across biotech, medtech, and digital health.</p><p>Host: Shamieraah Jamal</p><p>Editor: Dillon Chew</p><p>Podcast Team: Chi Dam, Alefiya Dohadwala, Chelsia Goh</p>